期刊文献+

小剂量米非司酮治疗围绝经期功能失调性子宫出血 被引量:10

Efficacy of lower dose mifepristone in treating dysfunctional uterine bleeding in perimenopausal period
下载PDF
导出
摘要 目的:探讨口服小剂量米非司酮治疗围绝经期功能失调性子宫出血的临床疗效。方法:82例围绝经期功能失调性子宫出血患者给予6.25mg米非司酮片口服,连续服药3个月。于治疗前及治疗1、2、3、6个月分别测定血清激素水平,观察月经情况,同时监测子宫内膜厚度。结果:米非司酮治疗患者服药期间均闭经,用药后患者血清雌二醇(E2)、孕酮(P)和泌乳素(PRL)的平均水平较用药前均有不同程度的下降(P<0.05);卵泡刺激素(FSH)、黄体生成素(LH)变化不明显(P>0.05),贫血得到纠正,无子宫内膜增厚。结论:6.25mg小剂量米非司酮可有效治疗围绝经期功能失调性子宫出血,具有一定的临床应用价值。 Objective: To investigate the efficacy of mifepristone in treating dysfunctional uterine bleeding in perimenopausal period. Methods: 82 patients with dysfunctional uterine bleeding in perimenopausal period were treated with 6.25 mg mifepristone daily for 3 months. Effects of mifepristone on inducing amenorrhea, the changes of endocrine and the pathology of endometrium were observed before treatment and after 1, 2, 3 and 6 months treatment. Results: All patients were amenorrhea during treatment with mifepristone. Serum estradiol (E2), progestone (P) and prolactin (PRL) level showed significantly decreased after treatment (P0.05). No significant changes of serum follicle-stimulating hormone (FSH) and luteotrophic hormone (LH) levels were found after 6 months treatment. The endometrium were atrophied and anemia was improved in patients after treatment. Conclusion: Treatment of lower dose mifepristone (6.25 mg, daily) is a safe and effective method for treating dysfunctional uterine bleeding in preimenopausal period.
出处 《中国当代医药》 2010年第21期63-65,共3页 China Modern Medicine
关键词 米非司酮 功能失调性子宫出血 围绝经期 Mifepristone Dysfunctional uterine bleeding Perimenopausal period
  • 相关文献

参考文献12

二级参考文献14

  • 1刘冬娥.女性围绝经期的生理和病理变化[J].中国实用妇科与产科杂志,2004,20(8):473-474. 被引量:249
  • 2廖爱华.米非司酮的作用机理及临床应用[J].实用妇产科杂志,1994,10(1):15-16. 被引量:532
  • 3张雪莲,倪江,罗宏志,刘润梅,吴嬿婉,李伟雄,程治平.酪氨酸、米非司酮和睾酮对大鼠颗粒细胞凋亡的影响[J].生殖医学杂志,1995,4(3):142-145. 被引量:118
  • 4朱四军,赵白鸽,谢衷明.RU486对下丘脑-垂体-卵巢-子宫内膜轴的功能影响[J].生殖与避孕,1995,15(4):243-248. 被引量:299
  • 5Ferencly A, Gecfand M. The biologic significance of cytocogic atgpia in progestogen-rteated endomerriac hyperplasia. Am Jobstet Gynecol, 1989,160.. 126-131.
  • 6Rein MS,Barbieri RL.Progesterone:a critical role in the pathogenesis of uterine myomas.Am J Obstet Gynecol,1995,172(1):14-18
  • 7Nayak NR,Ghosh D,Sengupta J.Effects of luteal phase administration of mifepristone (RU486) and prostaglandin analogue or inhibitor.Hum Reprod,1998,13(4):1047-1056
  • 8Van Vem JFHM,Hsiu TG,Chillik CF,et al.Contraceptive potential of RU486 by ovulation inhibition.Contraception,1989,40(1):171-184
  • 9Ghosh D,Kumar PG,Sengupta J.Effect of early luteal phase administration of mifepristone(RU486)on leukaemia inhibitory factor,transforming growth factor beta and vascular endothelial growth factor in the implantation stage endometrium of the rhesus monkey.J Endocrinol,1998,157(1):115-125
  • 10马青年,姜良,程治平.小鼠卵巢对酪氨酸的摄取与酪氨酸抗hCG致孕酮生成作用[J]动物学报,1984(02).

共引文献244

同被引文献51

引证文献10

二级引证文献68

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部